Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation
NCT06863402Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2026
- Primary completion
- Jun 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nemtabrutinib, pembrolizumab in Richter syndrome (RS), diffuse large B-cell lymphoma (DLBCL), sponsored by Roswell Park Comprehensive Cancer Center. Started Nov 2026; status: recruiting.
02
Drugs
nemtabrutinibpembrolizumab
03
Conditions
Richter syndrome (RS)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06863402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863402.